Personalis Extends Cash Position Into 2026, Provides Update on Key Initiatives

FREMONT, Calif.–(BUSINESS WIRE)–Personalis, Inc., a leader in advanced genomics for precision oncology (Nasdaq: PSNL), disclosed a reduction in headcount impacting approximately 20% of the company’s staff. By consolidating several functions for efficiency, this reduction is expected to reduce operating expenses by approximately $14 million annually. This action, along with the…
Click here to view original post